Literature DB >> 30255284

A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Peter Kenneth Gillman1.   

Abstract

This review appraises over 150 recent original papers reporting data that demonstrate the greatly reduced tyramine content of modern-day 'foods', about which the medical literature has a paucity of information. It discusses the cardiovascular pharmacology of tyramine and the characteristics, extent, risks, and treatment of the blood pressure increases that sometimes result from tyramine ingestion (the pressor response). In past decades, cheese was the only food associated with documented fatalities resulting from hypertension. Today, few foods contain problematically high tyramine levels, which is a result of changes in international food production techniques (especially the use of starter cultures), and hygiene regulations. Nowadays, even 'matured' cheeses are usually safe in healthy-sized portions. The mechanism by which tyramine may be produced in foods (by certain micro-organisms) is explained and hundreds of recent estimations of cheeses are reviewed. Numerous other previously inadequately documented foods are reviewed, including fish and soy sauces, salami-type sausages, dried meats, beers, wines, and various condiments. Evidence that the risk of harm from the pressor response has previously been overstated is reviewed, and the iatrogenic harms from hasty and aggressive treatment of hypertensive urgency are re-evaluated. Evidence now suggests that MAOIs are of comparable safety to many newer drugs and are straightforward to use. Previously held concerns about MAOIs are misplaced and some are of over-estimated consequence. The variability of pressor sensitivity to tyramine between individuals means that the knowledge and judgement of doctors, and some care, are still required.

Entities:  

Keywords:  Biogenic amines; Decarboxylating enzymes; Hypertension; Hypertensive emergency; Hypertensive urgency; Monoamine oxidase inhibitors; Tyramine

Mesh:

Substances:

Year:  2018        PMID: 30255284     DOI: 10.1007/s00702-018-1932-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  117 in total

1.  PARGYLINE HYDROCHLORIDE IN TREATMENT OF RESISTANT HYPERTENSION.

Authors:  J R VAN DYNE
Journal:  N Y State J Med       Date:  1965-06-15

Review 2.  Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants.

Authors:  Stephen M Stahl; Angela Felker
Journal:  CNS Spectr       Date:  2008-10       Impact factor: 3.790

3.  Age-specific suicide mortality following non-fatal self-harm: national cohort study in Sweden.

Authors:  D Tidemalm; K Beckman; M Dahlin; M Vaez; P Lichtenstein; N Långström; B Runeson
Journal:  Psychol Med       Date:  2014-11-26       Impact factor: 7.723

4.  A multiresidual method based on ion-exchange chromatography with conductivity detection for the determination of biogenic amines in food and beverages.

Authors:  Carmen Palermo; Marilena Muscarella; Donatella Nardiello; Marco Iammarino; Diego Centonze
Journal:  Anal Bioanal Chem       Date:  2012-10-09       Impact factor: 4.142

5.  Arterial blood pressure response to heavy resistance exercise.

Authors:  J D MacDougall; D Tuxen; D G Sale; J R Moroz; J R Sutton
Journal:  J Appl Physiol (1985)       Date:  1985-03

6.  Determination of Biogenic Amines in Cheese by Ion Chromatography with Tandem Mass Spectrometry Detection.

Authors:  Andrej Ščavničar; Irena Rogelj; Drago Kočar; Sevim Kse; Matevž Pompe
Journal:  J AOAC Int       Date:  2018-03-23       Impact factor: 1.913

7.  Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.

Authors:  R Zimmer
Journal:  Acta Psychiatr Scand Suppl       Date:  1990

8.  Intracranial haemorrhage in patients treated with monoamineoxidase inhibitors.

Authors:  J C De Villiers
Journal:  Br J Psychiatry       Date:  1966-02       Impact factor: 9.319

9.  Oxaprotiline: enantioselective noradrenaline uptake inhibition indicated by intravenous amine pressor tests but not alpha 2-adrenoceptor binding to intact platelets in man.

Authors:  I W Reimann; L Firkusny; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Tyramine pharmacokinetics and reduced bioavailability with food.

Authors:  Chad M VanDenBerg; Lawrence F Blob; Eva M Kemper; Albert J Azzaro
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

View more
  8 in total

Review 1.  The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.

Authors:  Vincent Van den Eynde; Peter Kenneth Gillman; Barry B Blackwell
Journal:  Psychopharmacol Bull       Date:  2022-05-31

2.  Preliminary Investigation of Biogenic Amines in Type I Sourdoughs Produced at Home and Bakery Level.

Authors:  Giuseppe Mannino; Fortunato Cirlincione; Raimondo Gaglio; Elena Franciosi; Nicola Francesca; Giancarlo Moschetti; Alberto Asteggiano; Claudio Medana; Carla Gentile; Luca Settanni
Journal:  Toxins (Basel)       Date:  2022-04-20       Impact factor: 5.075

3.  The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors.

Authors:  Vincent Van den Eynde
Journal:  J Neural Transm (Vienna)       Date:  2021-08-09       Impact factor: 3.575

4.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

5.  Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A.

Authors:  Muhammad Rafehi; Frank Faltraco; Johannes Matthaei; Thomas Prukop; Ole Jensen; Aileen Grytzmann; Felix G Blome; Ralf Günter Berger; Ulrich Krings; Stefan V Vormfelde; Mladen V Tzvetkov; Jürgen Brockmöller
Journal:  Front Pharmacol       Date:  2019-10-30       Impact factor: 5.810

6.  Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects.

Authors:  James Brown; Zhe Li; Xi Wang; Yu Jeong Kim; Yu-Chen Wang; Yanning Zuo; Weizhe Hong; Pin Wang; Bo Li; Lili Yang
Journal:  Front Pharmacol       Date:  2022-09-01       Impact factor: 5.988

Review 7.  Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.

Authors:  Dmitriy Matveychuk; Erin M MacKenzie; David Kumpula; Mee-Sook Song; Andrew Holt; Satyabrata Kar; Kathryn G Todd; Paul L Wood; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2021-04-10       Impact factor: 5.046

8.  Use of MAOIs in severe treatment-resistant depression: back to the old school.

Authors:  Jacob Cookey
Journal:  J Psychiatry Neurosci       Date:  2021-07-05       Impact factor: 6.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.